A Need to Meet Patient Expectations

Funding Information: Open access funding provided by Università degli Studi di Palermo within the Nicola Veronese reports personal fees from IBSA, Mylan, and Fidia outside of the submitted work. Cyrus Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB outside of the submitted work. Jean-Yves Reginster reports CRUI-CARE Agreement. Funding Information:grants from IBSA-Genevrier, Mylan, CNIEL, and Radius Health (through his institution); consulting fees from IBSA-Genevrier, Mylan, CNIEL, Radius Health, and Pierre Fabre; fees for participation in review activities from IBSA-Genevrier, Mylan, CNIEL, Radius Health, and Teva; and payment for lectures from Ag-Novos, CERIN, CNIEL, Dairy Research Council (DRC), Echolight, IBSA-Genevrier, Mylan, Pfizer Consumer Health, Teva, and Theramex outside of the submitted work. Olivier Bruyère reports grants or lecture fees from Amgen, Aptissen, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, Servier, SMB, TRB Chemedica, UCB, and Viatris outside of the submitted work. Ali Mobasheri declares personal fees from Abbott, Abbvie, Achē Laboratórios Farmacêuticos, Galapagos, GSK Consumer Healthcare, Kolon TissueGene, Laboratoires Expansciences, Merck, Pacira Biosciences, Pfizer, Sanofi, and Servier. François Rannou reports grants or lecture fees from Pierre Fabre, Mylan, MSD, Thuasne, IBSA, Pfizer, Genévrier, Expanscience, Scarcell, Skindermic, and Peptinov. Ida K. Haugen reports grants from Pfizer and is a consultant for Novartis outside of the submitted work. Elaine M. Dennison declares grants/fees from Pfizer, Lilly, UCB, and Viatris. Philip G. Conaghan is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (the views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health), and reports consultancies or lecture fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, GSK, Grunenthal, Pfizer, Novartis, and UCB. Nasser M. Al-Daaghri, Antonella Fioravanti, Sara Cheleschi, Jean-Pierre Pelletier, Maarten de Wit, Etienne Cavalier, Radmila Matijevic, Germain Honvo, Régis Pierre Radermecker, René Rizzoli, Jaime Branco, Andrea Laslop, María Concepción Prieto Yerro, Alberto Migliore, Gabriel Herrero-Beaumont, and Nicholas R. Fuggle declare that they have no conflicts of interest. Publisher Copyright: © 2022, The Author(s).Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the case of moderate to severe pain, a single intervention may not be sufficient to allay symptoms and improve quality of life. Examples include first-line, background therapy with symptomatic slow-acting drugs for OA (SYSADOAs) or non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) performed a review of a multimodal/multicomponent approach for knee OA therapy. This strategy is a particularly appropriate solution for the management of patients affected by knee OA, including those with pain and dysfunction reaching various thresholds at the different joints. The multimodal/multicomponent approach should be based, firstly, on different combinations of non-pharmacological and pharmacological interventions. Potential pharmacological combinations include SYSADOAs and NSAIDs, NSAIDs and weak opioids, and intra-articular treatments with SYSADOAs/NSAIDs. Based on the available evidence, most combined treatments provide benefit beyond single agents for the improvement of pain and other symptoms typical of knee OA, although further high-quality studies are required. In this work, we have therefore provided new, patient-centered perspectives for the management of knee OA, based on the concept that a multimodal, multicomponent, multidisciplinary approach, applied not only to non-pharmacological treatments but also to a combination of the currently available pharmacological options, will better meet the needs and expectations of patients with knee OA, who may present with various phenotypes and trajectories.publishersversionpublishe

Ships hull corrosion diagnosis from close measurements of electric potential in the water

International audienc

A Post-Processing Integral Formulation for the Computation of Magnetic Field in Conductors

International audienceWe present here an original method of computing the magnetic induction in a conductor thanks to a post-processing from the boundary elements method (BEM). The paper gives the main keys of the algorithm, from the theoretical aspect as well as the practical one. This general formulation is then applied to simulated cases and finally to a real underwater electric system under cathodic protection

A Post-processing Integral Formulation for the Computation of Magnetic Field in Conductors

International audienc

A Post-processing Integral Formulation for the Computation of Magnetic Field in Conductors

International audienc

Inversion improvement of a corrosion diagnosis thanks to an inequality constraint

International audienceThis article presents a direct application of a Tikhonov inversion with a quadratic constraint applied in the case of a corrosion diagnosis. The main originality of this method is to inject physical information during the inversion to automatically restrict the Tikhonov parameter space. This application is then tested on a real case of corrosion diagnosis from electrical measurements in the water

Corrosion Diagnosis of a Ship Mock-Up From Near Electric-Field Measurements

International audienceWe present here an original application linking an electrochemical phenomenon and the computational aspect of electromagnetic fields to provide a corrosion diagnosis of a protected underwater steel structure. This is done with the pairing of a boundary element method and the resolution of an inverse problem. After a defined operating time, it is mandatory to check an underwater steel structure. Sadly, current examinations techniques require immobilizing the structure for a long time and are less efficient. The purpose of this paper is to replace this checking by a series of close electrical measurements in the conducting water which provides a corrosion diagnosis of the structure. The new method introduced ensures great time-savings but also an accuracy never reached before. This paper presents this numerical method and its checking through real electrical measurements on a frigate mock-up

Ships Hull Corrosion Diagnosis From Close Measurements of Electric Potential in the Water

International audienceWe present here an original method to search the corroded zones of an underwater steel structure. Nowadays, after a defined navigation period, a vessel is placed in dry dock, to examine its hull state, find the damaged areas and then paint them. This step of identification, very long and relatively inefficient, could be replaced by a series of electrical measurements which would be processed to get clues about the state of the hull. Those results are obtained thanks to the study of the cathodic protection system equipped on the hull. This new method allows a great timesaving but also a precision never reached before